Read this first: IGF-1 LR3 is not mecasermin

Mecasermin (Increlex) is approved recombinant human IGF-1, with a sequence identical to the natural hormone. IGF-1 LR3 is a deliberately altered analogue with a swapped residue and an extra 13 amino acid tail, and it has never been approved for human use anywhere. Evidence, doses and safety data for one do not transfer to the other (PMID 33587816).

IGF-1 LR3

A laboratory analogue of human IGF-1, altered at position 3 and extended at the N terminus so it largely evades the IGF binding proteins. It is sold as a research reagent, no human trial has ever tested it, and it is not the approved drug mecasermin.

Last updated: September 2026

What is IGF-1 LR3?

IGF-1 LR3, short for Long R3 insulin-like growth factor 1, is a recombinant protein analogue of human IGF-1, not a small molecule. It differs from the natural hormone in two ways: the glutamic acid at position 3 is swapped for arginine, and a 13 amino acid peptide is added to the N terminus (PMID 7513341). Add that tail to the 70 amino acid hormone and you get the 83 residue, roughly 9.1 kDa protein the research reagent spec sheet describes, expressed in E. coli. You can compare it with the rest of the compounds in our peptide library.

That extension is not random. The Long analogues were built in the early 1990s from the first 11 amino acids of methionyl porcine growth hormone followed by the dipeptide Val-Asn, which is what makes the tail 13 residues long, and the R3 refers to the arginine at position 3 (PMID 1378742). The published extension sequence, Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn, matches the sequence today's suppliers print for the product residue for residue (PMID 8948444).

Here is the part vendor copy routinely gets backwards. The modifications do not make IGF-1 LR3 grip the IGF-1 receptor harder. They make it bind the IGF binding proteins much more weakly, so more of it circulates free. The original characterisation concluded that reduced binding to IGF-binding proteins rather than increased receptor binding is the likely explanation for the greater biological potency (PMID 1311930), and one study found LR3 actually binds about 3 fold less well than IGF-1 to the type 1 receptor (PMID 1371669).

Its real job is unglamorous: it is a laboratory and bioprocessing reagent, sold For Research Use Only and Not for use in diagnostic procedures, and used as an insulin substitute to keep Chinese hamster ovary cells alive in serum free manufacturing (PMID 11027158). It is also, and this matters, not mecasermin. Mecasermin (Increlex) is approved recombinant human IGF-1 whose sequence is identical to the natural hormone; IGF-1 LR3 is a deliberately altered molecule, so evidence for one does not carry to the other (PMID 33587816). For the wider growth hormone and IGF family, see our HGH peptides guide.

How It Works

Free fraction, not a firmer grip. IGF-1 LR3 largely escapes the IGF binding proteins that normally hold IGF-1 in reserve, so more of a given amount stays free to reach the IGF-1 receptor. The original papers concluded this reduced binding, not any increase in receptor binding, explains the greater potency (PMID 1311930).

Potency on paper, in animals. In growing rats, 44 µg/day of LR3 produced effects similar to a much larger 278 µg/day of ordinary IGF-1 over 14 days by subcutaneous pump, roughly a 6 fold difference by weight (animal study, rat, subcutaneous, PMID 8371075). Whether that carries to a person is unknown, because the study has never been done.

Fast in, fast out. Low binding protein affinity shortens residence time. After a single intramuscular dose in rats, LR3 was largely gone within about 4 hours, far faster than related analogues (animal study, rat, intramuscular, PMID 33587816).

It can suppress the axis it is sold to boost. Across species the most reproducible physiological effect is lower insulin, and in pigs and calves it also lowered growth hormone (animal study, pig, infusion, PMID 9488001).

What the Studies Measured

Increased body weight in normal fetal sheep infused at 6.6 µg/kg/h for a week, but alongside lower insulin and lower glucose stimulated insulin secretion (animal study, sheep, infusion, PMID 39679943)
Heavier individual organs, including heart, adrenal gland and spleen, in fetal sheep, while whole fetal body weight did not differ from controls and umbilical amino acid uptake fell (animal study, sheep, intravenous infusion, PMID 33427051)
Small and large intestine weight up by about 20% in rats infused at 2.5 mg/kg/day for three days, the most reproducible LR3 effect across species (animal study, rat, infusion, PMID 8549937)
About 2.5 to 3 fold greater potency than ordinary IGF-1 at restoring growth in diabetic rats, measured against an IGF-1 high dose of 695 µg/day (animal study, rat, osmotic pump, PMID 7683875)
A modest increase in lactation capacity in mice given subcutaneous LR3; the abstract states no dose (animal study, mouse, subcutaneous, PMID 18577570)
No improvement in growth in growth restricted fetal sheep infused at 1.17 µg/kg/h for a week (animal study, sheep, infusion, PMID 39679943)
Growth inhibition, not growth, in finisher pigs at 180 µg/kg/day, which the authors tied to suppressed growth hormone (animal study, pig, infusion, PMID 9488001)
At the bench, it sustains Chinese hamster ovary cell cultures as an insulin substitute, its actual documented commercial use (in vitro, PMID 11027158)

Animal Study Doses in the Literature

Phase	Dose	Frequency	Duration
Fetal sheep, normal	6.6 µg/kg/h (animal study, sheep, infusion, PMID 39679943)	Continuous infusion into the fetal circulation	1 week; increased body weight but lowered insulin and GSIS (PMID 39679943)
Fetal sheep, growth restricted	1.17 µg/kg/h (animal study, sheep, infusion, PMID 39679943)	Continuous infusion, LR3 n=7 vs vehicle n=7	1 week; body weight, insulin, glucose and GSIS not different from vehicle (PMID 39679943)
Rat, growing female	44 µg/day (animal study, rat, subcutaneous, PMID 8371075)	Subcutaneous osmotic pump	14 days; effects similar to 278 µg/day of ordinary IGF-1 (PMID 8371075)
Rat, intestinal growth	2.5 mg/kg/day (animal study, rat, infusion, PMID 8549937)	Infusion	3 days; small and large intestine weight up about 20% (PMID 8549937)
Rat, cardiovascular	125 µg/kg/h (animal study, rat, intravenous, PMID 9415069)	Intravenous infusion	20 to 60 min; mean arterial pressure fell 15% to 25% (PMID 9415069)
Rat, single injection	100 µg/kg (animal study, rat, intramuscular, PMID 33587816)	Single intramuscular dose	Cleared within about 4 hours (PMID 33587816)
Pig, finisher	180 µg/kg/day (animal study, pig, infusion, PMID 9488001)	Infusion into 55 kg finisher pigs	4 days; decreased daily gain and food intake, suppressed GH (PMID 9488001)
Guinea pig	120 µg/day (animal study, guinea pig, infusion, PMID 7561636)	Continuous infusion	7 days; organ weights up, whole body growth not stimulated (PMID 7561636)
Calf, neonatal	50 µg/kg/day (animal study, calf, subcutaneous and oral, PMID 9252489)	Subcutaneous vs oral, compared directly	7 days; plasma rose after subcutaneous but not oral; oral inert (PMID 9252489)
Mouse, Alzheimer model	dose not stated in the abstract (animal study, mouse, intranasal, PMID 39610283)	Intranasal, 7 months	Improved body composition but no cognitive benefit in 5XFAD mice (PMID 39610283)

Every figure below is from an animal study, listed with the species and route the paper used. None is a human dose, and none of these papers scales an animal dose to a person. This table is educational, not a recommendation or a protocol. Any dose, route, or decision to use a compound belongs with a licensed prescriber.

Side Effects

Signals from animal studies

⚠Lower insulin and reduced glucose stimulated insulin secretion, the single most consistent effect, across fetal sheep, calves and pigs; in fetal sheep it persisted in isolated islets after a week of exposure (animal study, sheep, infusion, PMID 33938236)
⚠Lower mean arterial blood pressure, by 15% to 25%, with sharply altered regional blood flow, after intravenous LR3 in rats at 125 µg/kg/h (animal study, rat, intravenous, PMID 9415069)
⚠Suppression of the growth hormone axis it is marketed to raise: in pigs mean plasma growth hormone fell 23% and its pulse area fell 60% (animal study, pig, infusion, PMID 9488001)
⚠Growth inhibition rather than growth in finisher pigs at 180 µg/kg/day, with lower daily weight gain and food intake (animal study, pig, infusion, PMID 9488001)

From the compound class and the mecasermin label (a different molecule)

•Class level, from a 2026 review that names IGF-1 LR3: reported endocrine and metabolic disturbances, fluid retention, myalgia or arthralgia, and injection site reactions across this compound class, plus biologically plausible but unproven concerns about promoting cell growth (attributed to the class, PMID 42395176)
•Mecasermin label, a different approved molecule, shown only for context: hypoglycemia in 42% of 71 pediatric subjects, with severe hypoglycemia and seizures in a few, plus label warnings for lymphoid hypertrophy, slipped capital femoral epiphysis, and postmarketing reports of malignant neoplasms (mecasermin label, not IGF-1 LR3 data)

Legal Status and Hard Stops

✕Prohibited in sport at all times. The 2026 World Anti-Doping Code Prohibited List, in force since 1 January 2026, bans IGF-1 and its analogues under section S2.3 as non specified substances, in and out of competition (WADA 2026 Prohibited List).
✕A routine doping control target. Long R3 IGF-1 is named in validated urine and blood test methods used in sport (PMID 26382721).
✕No approved human use anywhere, and every supplier, research reagent and consumer alike, labels it not for human consumption (PMID 33587816).
✕No human safety data at all. Nobody can say who is most at risk, because the studies that would answer that have never been run (PMID 42395176).

Time Course, and Why There Is No Human One

Human data

None. No clinical trial has given IGF-1 LR3 to a person, so there is no human time course to describe (PMID 33587816).

Hours (animals)

In rats a single intramuscular dose is largely cleared within about 4 hours, faster than related IGF-1 analogues (animal study, rat, intramuscular, PMID 33587816).

About 1 week (animals)

Most quantified studies ran roughly one week by continuous infusion. Effects were often organ specific and came with lower insulin, while whole body growth frequently did not change (animal study, guinea pig, infusion, PMID 7561636).

Direction varies

Effect direction depends on species and model: weight gain in neonatal pigs, growth inhibition in finisher pigs, and no growth in growth restricted fetal sheep (animal study, pig and sheep, infusion, PMID 9488001).

Notes from Ho Chi Minh City

In HCMC gym and forum chatter, IGF-1 LR3 gets talked about as a stronger, longer acting cousin of the growth hormone peptides, and the vendor pages lean hard into that story. The research tells a duller and more important one. This is a cell culture reagent that was never tested in a person, its headline potency comes from dodging the binding proteins rather than gripping the receptor, and when it has actually gone into animals the results run from mixed to negative, including outright growth inhibition in finisher pigs (PMID 9488001). The part that should stop anyone is what the doping labs found when they opened black market vials: oxidised and unpurified material, and in one case laboratory surplus with a purification tag still attached, not a drug (PMID 20675162). I am not laying out a protocol here, because there is no human protocol to lay out. Dose, route, and whether to touch it at all are decisions for a licensed prescriber, and in sport it is banned outright.

IGF-1 LR3 in Vietnam

In Vietnam specifically there is no legitimate retail path to IGF-1 LR3. Long Chau, the country's largest pharmacy chain, returns nothing for the approved IGF-1 medicine names mecasermin and Increlex, and a search for IGF-1 LR3 itself surfaces an unrelated alkaline battery whose product code happens to read LR3, which is about as clear as a null gets (pharmacy chain on-site search, fetched September 2026). IGF-1 does exist in Vietnamese clinical practice, but only as a diagnostic blood test a doctor orders to assess growth hormone and pituitary function, as described by MEDLATEC and by Long Chau's vaccination arm, not as a therapy anyone administers. Its registration status with the Drug Administration of Vietnam could not be determined from here, so this page makes no claim in either direction, and no Vietnamese retail price exists to quote.

FAQ

Q: Is IGF-1 LR3 the same as mecasermin or Increlex?

A: No. Mecasermin, sold as Increlex, is approved recombinant human IGF-1 whose sequence is identical to the natural 70 amino acid hormone. IGF-1 LR3 has a swapped residue and a 13 amino acid tail, runs to 83 amino acids, and has never been approved for human use. For reference only, the mecasermin label describes a pediatric starting dose of 0.04 to 0.08 mg/kg twice daily up to a maximum of 0.12 mg/kg twice daily (approved label dose for mecasermin, a different molecule, DailyMed). That figure belongs to mecasermin, not to IGF-1 LR3, and does not transfer.

Q: Is there a standard IGF-1 LR3 dosage?

A: No. There is no established human dose, because there is no human study. The only real dosing data is from animals and is always tied to a species and a route: for example 6.6 µg/kg/h infused into normal fetal sheep for a week (animal study, sheep, infusion, PMID 39679943), 2.5 mg/kg/day infused into rats for three days (animal study, rat, infusion, PMID 8549937), or 50 µg/kg/day in calves, where the oral route did nothing systemically (animal study, calf, subcutaneous and oral, PMID 9252489). None of these papers scales its figure to a person.

Q: Does IGF-1 LR3 build muscle?

A: No study shows that in a person, and the animal record is mixed. It grew individual organs without growing the whole body in guinea pigs (animal study, guinea pig, infusion, PMID 7561636), inhibited growth in finisher pigs (animal study, pig, infusion, PMID 9488001), and in wasted rats it was 'barely equipotent' with ordinary IGF-1 at reversing muscle loss despite its headline potency (animal study, rat, subcutaneous, PMID 8708565). Its most consistent effect across species is lowering insulin, not adding muscle.

Q: Why is it sold as research use only?

A: Because that is what it is. IGF-1 LR3 was developed as a laboratory and bioprocessing reagent, and its main documented commercial role is as an insulin substitute for growing Chinese hamster ovary cells in serum free manufacturing (PMID 11027158). Reagent suppliers label it For Research Use Only and Not for use in diagnostic procedures, and consumer peptide vendors add their own not for human consumption warnings. For the wider growth hormone and IGF family, see our HGH peptides guide.

Q: Is IGF-1 LR3 legal or sold in pharmacies in Vietnam?

A: It is not stocked by Long Chau, Vietnam's largest pharmacy chain: a search there for IGF-1 LR3 returns an unrelated alkaline battery, and the approved IGF-1 medicine names return nothing (pharmacy chain on-site search, fetched September 2026). Its registration status with the Drug Administration of Vietnam could not be determined here, so we make no claim either way. IGF-1 does appear in Vietnamese healthcare, but only as a diagnostic blood test a doctor orders, not as a treatment. In sport it is prohibited at all times. See the peptide FAQ for sourcing and COA questions.

Where People Get It, and What Is Actually in the Vial

Two supply channels exist, and neither is a Vietnamese pharmacy. Research reagent suppliers sell it for laboratory use only, labelled 'For Research Use Only. Not for use in diagnostic procedures.' Consumer peptide vendors sell 1 mg vials for roughly $79.99 to $150.00, and every one fetched disclaims human use in its own words, for example 'Not for human or animal consumption' (vendor product pages, fetched September 2026). Independent doping laboratories that analysed black market product reported oxidised, low quality and unpurified peptide (PMID 33587816), and in one analysed vial found His tagged laboratory surplus rather than a drug (PMID 20675162). A national anti doping agency adds that products claiming to contain IGF-1 'may not actually contain IGF-1 at all, or may contain a very diluted form of the substance, or other potentially harmful substances' (USADA position statement). Long Chau, Vietnam's largest pharmacy chain, lists none of it.

See the peptide COA and sourcing FAQ

Related Peptides

CJC-1295 Ipamorelin Tesamorelin Tesamorelin Peptide Library

Research & Sources

Several insulin-like growth factor-I analogues and complexes of IGF-I and -II with IGFBP-3 fail to mimic the effect of growth hormone upon lactation in the rat · The Journal of Endocrinology (1994) (PMID: 7513341)
States the two modifications that define Long R3 IGF-I: the Glu to Arg swap at position 3 and the 13 amino acid N-terminal extension.
Mutations in the B-domain of insulin-like growth factor-I influence the oxidative folding to yield products with modified biological properties · The Biochemical Journal (1995) (PMID: 8948444)
Gives the literal 13 residue extension sequence, Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn.
Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency · Journal of Molecular Endocrinology (1992) (PMID: 1378742)
Original construction of the Long analogues from pGH(1-11) plus Val-Asn, and the source of the Long, Gly3, Arg3 naming.
Production and characterization of recombinant IGF-I and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, expressed in Escherichia coli as fusion proteins · Journal of Molecular Endocrinology (1992) (PMID: 1311930)
Concludes the greater potency is due to reduced binding to IGF-binding proteins, not increased receptor binding.
Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats · The Biochemical Journal (1992) (PMID: 1371669)
LR3IGF-I about 2.5 fold more potent than IGF-I, yet binds about 3 fold less well than IGF-I to the type 1 IGF receptor.
Human IGF-I LR3 Recombinant Protein, catalogue number 100-11R3 (research reagent spec sheet) · PeproTech / Thermo Fisher Scientific (2026) Link
Current commercial spec sheet: 83 residues, about 9.1 kDa, expressed in E. coli, labelled For Research Use Only, Not for use in diagnostic procedures.
Effects of insulin and LongR3 on serum-free Chinese hamster ovary cell cultures expressing two recombinant proteins · Biotechnology Progress (2000) (PMID: 11027158)
Documents the actual commercial role: an insulin substitute for CHO cell manufacturing.
Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes · Drug Testing and Analysis (2021) (PMID: 33587816)
States the analogues were never approved for use in humans; gives the single intramuscular rat pharmacokinetics; reports oxidised black market forms.
Clinical trial registry searches for the Long R3 IGF-1 cluster with mecasermin positive controls (ClinicalTrials.gov, EudraCT, EU CTIS, WHO ICTRP) · Trial registry query records (2026) Link
Zero human trials of IGF-1 LR3 across all four registries; every mecasermin control query returned a non-zero count from the same endpoint.
The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration · Frontiers in Endocrinology (2026) (PMID: 42395176)
Names IGF-1 LR3 explicitly; lists class level adverse effects; places these compounds at the complete absence of human studies tier.
INCRELEX (mecasermin) injection, US prescribing information (a different, approved molecule, shown for contrast only) · DailyMed (2025) Link
Mecasermin is rhIGF-1 identical to the natural hormone, 70 amino acids; label starting dose 0.04 to 0.08 mg/kg twice daily. This is not IGF-1 LR3.
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep · American Journal of Physiology. Endocrinology and Metabolism (2025) (PMID: 39679943)
Fetal sheep by infusion: 6.6 microg/kg/h in normal fetuses raised weight but lowered insulin and GSIS; 1.17 microg/kg/h did not improve growth in growth-restricted fetuses.
IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus · American Journal of Physiology. Endocrinology and Metabolism (2021) (PMID: 33427051)
Fetal sheep, 1 week intravenous infusion: heart, adrenal and spleen weights up, insulin and umbilical amino acid uptake down, fetal weight not different.
Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect · American Journal of Physiology. Endocrinology and Metabolism (2021) (PMID: 33938236)
Fetal sheep, 1 week infusion: insulin suppression persisted in isolated islets. Dose figure not stated in the abstract.
Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats · The Journal of Endocrinology (1993) (PMID: 8371075)
Rat, 14 day subcutaneous osmotic pump: 44 microg/day of LR3IGF-I produced effects similar to 278 microg/day of ordinary IGF-I.
Administration of IGF-I peptides for three days stimulates proliferation of the small intestinal epithelium in rats · Gut (1995) (PMID: 8549937)
Rat, 3 day infusion at 2.5 mg/kg/day: LR3IGF-I raised small and large intestine weight by about 20%.
Effects of insulin-like growth factor-I and LR3IGF-I on regional blood flow in normal rats · The Journal of Endocrinology (1997) (PMID: 9415069)
Rat, intravenous at 125 microg/kg/h: mean arterial blood pressure fell 15% to 25%, with large shifts in regional blood flow.
IGF-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects · The Biochemical Journal (1993) (PMID: 7683875)
Streptozotocin diabetic rats, mini-osmotic pump: variants 2.5 to 3 times more potent than IGF-I, measured against an IGF-I high dose of 695 microg/day.
Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection · The Journal of Endocrinology (1996) (PMID: 8708565)
Rat: continuous infusion outperformed injection; LR3IGF-I was barely equipotent with IGF-I for reversing dexamethasone muscle loss.
Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs · The Journal of Endocrinology (1997) (PMID: 9488001)
Finisher pigs, 4 day infusion at 180 microg/kg/day: decreased daily gain and food intake; mean plasma GH down 23% and GH peak area down 60%.
Long R3 IGF-I infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig · The Journal of Endocrinology (1995) (PMID: 7561636)
Guinea pig, 7 day infusion at 120 microg/day: fractional organ weights up, overall growth not stimulated.
The somatotropic axis in neonatal calves can be modulated by nutrition, growth hormone, and Long-R3-IGF-I · The American Journal of Physiology (1997) (PMID: 9252489)
Calf, 50 microg/kg/day for 7 days subcutaneous vs oral: plasma rose after subcutaneous but not oral dosing; oral was inert systemically.
Enhancement of maternal lactation performance in the mouse by mouse GH and long-R3-IGF-I is linked to changes in mammary signaling and gene expression · The Journal of Endocrinology (2008) (PMID: 18577570)
Mouse, subcutaneous injection: a modest increase in lactation capacity. Dose figure not stated in the abstract.
Intranasal long R3 IGF-1 promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice · Journal of Alzheimer’s Disease (2025) (PMID: 39610283)
Mouse, intranasal for 7 months: improved body composition but no cognitive benefit. Dose figure not stated in the abstract.
Detection of His-tagged Long-R3-IGF-I in a black market product · Growth Hormone & IGF Research (2010) (PMID: 20675162)
A black market injection vial contained His-tagged Long-R3-IGF-I, likely a by-product of biochemical studies rather than a drug made for injection.
Expanded test method for peptides greater than 2 kDa employing immunoaffinity purification and LC-HRMS/MS · Drug Testing and Analysis (2015) (PMID: 26382721)
Confirms longR3-IGF-I is a named target analyte in validated sports drug testing methods.
The 2026 Prohibited List, World Anti-Doping Code (English text via Austrian Federal Law Gazette BGBl. III Nr. 219/2025) · World Anti-Doping Agency (2025) Link
Section S2.3 bans IGF-1 and its analogues at all times, in and out of competition, as non specified substances. In force 1 January 2026.
IGF-1 and the World Anti-Doping Agency Prohibited List (agency position statement carrying a historical-reference disclaimer) · United States Anti-Doping Agency (n.d.) Link
Notes that products claiming to contain IGF-1 may not actually contain it or may contain other substances. Quoted as an agency position; current list wording is the 2026 WADA list above.
Nha thuoc Long Chau on-site product search for IGF-1, IGF-1 LR3, mecasermin and Increlex · Long Chau pharmacy chain (2026) Link
Mecasermin and Increlex return zero. The IGF-1 LR3 query top result is an unrelated alkaline battery whose product code reads LR3.
Consumer research-peptide vendor product pages for IGF-1 LR3 · Vendor product pages (2026) Link
1 mg vials priced roughly $79.99 to $150.00 across sellers; every page fetched disclaims human use and states research use only.
Xet nghiem IGF-1 danh gia hormone tang truong (IGF-1 as a diagnostic blood test in Vietnam) · MEDLATEC (2026) Link
IGF-1 appears in Vietnamese healthcare as a diagnostic test to assess growth hormone and pituitary function, not as a therapy.
Xet nghiem IGF-1 la gi, quy trinh thuc hien xet nghiem IGF-1 (IGF-1 diagnostic test explainer) · Tiem chung Long Chau (2026) Link
Describes IGF-1 as a test a doctor orders when a growth hormone or pituitary disorder is suspected. No treatment offering.

Important Disclaimer

Educational content only. Not medical advice. IGF-1 LR3 has never been approved for human use in any market, and no human clinical trial has ever tested it. It is sold only as a laboratory research reagent, labelled not for human use. It is not stocked by Long Chau, Vietnam’s largest pharmacy chain, and its registration status with the Drug Administration of Vietnam could not be determined here in either direction. In sport it is prohibited at all times. Consult a licensed physician before any use.